Search

Your search keyword '"Matsumoto, Shingo"' showing total 1,442 results
Start Over Author "Matsumoto, Shingo"
1,442 results on '"Matsumoto, Shingo"'

5. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

Author

Shi, Jianxin, Shiraishi, Kouya, Choi, Jiyeon, Matsuo, Keitaro, Chen, Tzu-Yu, Dai, Juncheng, Hung, Rayjean J, Chen, Kexin, Shu, Xiao-Ou, Kim, Young Tae, Landi, Maria Teresa, Lin, Dongxin, Zheng, Wei, Yin, Zhihua, Zhou, Baosen, Song, Bao, Wang, Jiucun, Seow, Wei Jie, Song, Lei, Chang, I-Shou, Hu, Wei, Chien, Li-Hsin, Cai, Qiuyin, Hong, Yun-Chul, Kim, Hee Nam, Wu, Yi-Long, Wong, Maria Pik, Richardson, Brian Douglas, Funderburk, Karen M, Li, Shilan, Zhang, Tongwu, Breeze, Charles, Wang, Zhaoming, Blechter, Batel, Bassig, Bryan A, Kim, Jin Hee, Albanes, Demetrius, Wong, Jason YY, Shin, Min-Ho, Chung, Lap Ping, Yang, Yang, An, She-Juan, Zheng, Hong, Yatabe, Yasushi, Zhang, Xu-Chao, Kim, Young-Chul, Caporaso, Neil E, Chang, Jiang, Ho, James Chung Man, Kubo, Michiaki, Daigo, Yataro, Song, Minsun, Momozawa, Yukihide, Kamatani, Yoichiro, Kobayashi, Masashi, Okubo, Kenichi, Honda, Takayuki, Hosgood, Dean H, Kunitoh, Hideo, Patel, Harsh, Watanabe, Shun-ichi, Miyagi, Yohei, Nakayama, Haruhiko, Matsumoto, Shingo, Horinouchi, Hidehito, Tsuboi, Masahiro, Hamamoto, Ryuji, Goto, Koichi, Ohe, Yuichiro, Takahashi, Atsushi, Goto, Akiteru, Minamiya, Yoshihiro, Hara, Megumi, Nishida, Yuichiro, Takeuchi, Kenji, Wakai, Kenji, Matsuda, Koichi, Murakami, Yoshinori, Shimizu, Kimihiro, Suzuki, Hiroyuki, Saito, Motonobu, Ohtaki, Yoichi, Tanaka, Kazumi, Wu, Tangchun, Wei, Fusheng, Dai, Hongji, Machiela, Mitchell J, Su, Jian, Kim, Yeul Hong, Oh, In-Jae, Lee, Victor Ho Fun, Chang, Gee-Chen, Tsai, Ying-Huang, Chen, Kuan-Yu, Huang, Ming-Shyan, Su, Wu-Chou, Chen, Yuh-Min, Seow, Adeline, Park, Jae Yong, and Kweon, Sun-Seog

Subjects
Genetics, Cancer, Clinical Research, Human Genome, Prevention, Lung, Lung Cancer, Tobacco, Tobacco Smoke and Health, 2.1 Biological and endogenous factors, Aetiology, Respiratory, Humans, Genome-Wide Association Study, Genetic Predisposition to Disease, Adenocarcinoma of Lung, Asia, Eastern, Lung Neoplasms, Polymorphism, Single Nucleotide
Abstract

Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset (n = 115) identified novel candidate genes, including FADS1 at 11q12 and ELF5 at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking (Pinteraction = 0.0058). These findings provide new insights into the etiology of lung adenocarcinoma in individuals from East Asian populations, which could be important in developing translational applications.

Published
2023

10. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia

Author

Okahisa, Masanobu, Udagawa, Hibiki, Matsumoto, Shingo, Kato, Terufumi, Yokouchi, Hiroshi, Furuya, Naoki, Kanemaru, Ryota, Toyozawa, Ryo, Nishiyama, Akihiro, Ohashi, Kadoaki, Miyamoto, Shingo, Nishino, Kazumi, Nakamura, Atsushi, Iwama, Eiji, Niho, Seiji, Oi, Hajime, Sakai, Tetsuya, Shibata, Yuji, Izumi, Hiroki, Sugiyama, Eri, Nosaki, Kaname, Umemura, Shigeki, Zenke, Yoshitaka, Yoh, Kiyotaka, Kah Mun Low, Grace, Zhuo, Jianmin, and Goto, Koichi

Published
2024
Full Text
View/download PDF

12. Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma

Author

Tanaka, Yu, Nakai, Tokiko, Suzuki, Ayako, Kagawa, Yosuke, Noritake, Osamu, Taki, Tetsuro, Hashimoto, Hiroko, Sakai, Tetsuya, Shibata, Yuji, Izumi, Hiroki, Nosaki, Kaname, Udagawa, Hibiki, Zenke, Yoshitaka, Matsumoto, Shingo, Yoh, Kiyotaka, Miyazaki, Saori, Sakamoto, Naoya, Sakashita, Shingo, Kojima, Motohiro, Watanbe, Reiko, Tsuboi, Masahiro, Goto, Koichi, and Ishii, Genichiro

Published
2023
Full Text
View/download PDF

22. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study

Author

Tamiya, Yutaro, Matsumoto, Shingo, Zenke, Yoshitaka, Yoh, Kiyotaka, Ikeda, Takaya, Shibata, Yuji, Kato, Terufumi, Nishino, Kazumi, Nakamura, Atsushi, Furuya, Naoki, Miyamoto, Shingo, Kuyama, Shoichi, Nomura, Shogo, Ikeno, Takashi, Udagawa, Hibiki, Sugiyama, Eri, Nosaki, Kaname, Izumi, Hiroki, Sakai, Tetsuya, Hashimoto, Naozumi, and Goto, Koichi

Published
2023
Full Text
View/download PDF

26. Glasgow prognostic score can be a prognostic indicator after percutaneous coronary intervention: a two-center study in Japan

Author

Noike, Ryota, Amano, Hideo, Suzuki, Shinya, Kano, Hiroto, Oikawa, Yuji, Yajima, Junji, Hirano, Shojiro, Kojima, Yoshimasa, Oka, Yosuke, Aikawa, Hiroto, Matsumoto, Shingo, Yabe, Takayuki, Okubo, Ryo, Nakanishi, Rine, Arita, Takuto, Yagi, Naoharu, Kishi, Mikio, Semba, Hiroaki, Matsuno, Shunsuke, Kato, Yuko, Otsuka, Takayuki, Uejima, Tokuhisa, Matsuhama, Minoru, Iida, Mitsuru, Yamashita, Takeshi, and Ikeda, Takanori

Published
2022
Full Text
View/download PDF

27. The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma

Author

Tamiya, Yutaro, Nakai, Tokiko, Suzuki, Ayako, Mimaki, Sachiyo, Tsuchihara, Katsuya, Sato, Kei, Yoh, Kiyotaka, Matsumoto, Shingo, Zenke, Yoshitaka, Nosaki, Kaname, Izumi, Hiroki, Shibata, Yuji, Sakai, Tetsuya, Taki, Tetsuro, Miyazaki, Saori, Watanabe, Reiko, Sakamoto, Naoya, Sakashita, Shingo, Kojima, Motohiro, Hashimoto, Naozumi, Tsuboi, Masahiro, Goto, Koichi, and Ishii, Genichiro

Published
2022
Full Text
View/download PDF

31. Phosphorus Dynamics in Japanese Blueberry Field: Long-Term Accumulation and Fractionation across Soil Types and Depths.

Author

Lu, Chun, Sugihara, Soh, Tanaka, Haruo, Tajima, Ryosuke, Matsumoto, Shingo, and Ban, Takuya

Subjects
FOREST soils, SOIL dynamics, PHOSPHORUS in soils, SOIL depth, SOIL classification
Abstract

Effective phosphorus (P) management is crucial for optimal blueberry production. However, a comprehensive understanding of phosphorus distribution across soil depths and types after two decades of blueberry cultivation remains a challenge. This study examines pH, EC, SOC (soil organic carbon), Total N (total nitrogen), and phosphorus fractions in soils from Japanese blueberry fields that have been cultivated for over 20 years. The soils selected for this study represent typical soils from long-term blueberry-growing regions in Japan, ensuring the relevance of the findings to these key agricultural areas. Soil samples were gathered from depths of 0–30 cm and 30–60 cm, revealing significant variations in phosphorus content that are influenced by soil properties and fertilization history. Soil types such as KS (Kuroboku soils) and FS (Fluvic soils) show higher Total P accumulation in deeper layers, whereas BFS (Brown Forest soils) and RYS (Red-Yellow soils) accumulate more in shallower layers. Long-term cultivation has led to greater non-labile phosphorus (NLP) accumulation in shallower layers of KS, BFS, and FS soils, indicating strong phosphorus fixation. BFS soil also exhibits increased organic phosphorus (NaOH-Po) at deeper depths. NaOH-Po and NaHCO3-Po, through their interactions with EC and pH, critically modulate the transformation of NLP into labile phosphorus (LP), thereby influencing overall phosphorus and nitrogen dynamics in the soil. These findings underscore the importance of tailored phosphorus fertilization strategies based on blueberry field characteristics, providing a basis for low-input phosphorus fertilization approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.

Author

Matsumoto, Shingo, Henderson, Alasdair D., Shen, Li, Kondo, Toru, Yang, Mingming, Campbell, Ross T., Anand, Inder S., Boer, Rudolf A., Desai, Akshay S., Lam, Carolyn S.P., Maggioni, Aldo P., Martinez, Felipe A., Packer, Milton, Redfield, Margaret M., Rouleau, Jean L., Van Veldhuisen, Dirk J., Vaduganathan, Muthiah, Zannad, Faiez, Zile, Michael R., and Jhund, Pardeep S.

Subjects
*HEART failure patients, *ATRIAL fibrillation, *HEART failure, *VENTRICULAR ejection fraction, *HEART beat
Abstract

ABSTRACT Aims Methods and results Conclusions In the absence of randomized trial evidence, we performed a large observational analysis of the association between beta‐blocker (BB) use and clinical outcomes in patients with heart failure (HF) and mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF).We pooled individual patient data from four large HFmrEF/HFpEF trials (I‐Preserve, TOPCAT, PARAGON‐HF, and DELIVER). The primary outcome was the composite of cardiovascular death or HF hospitalization. Among the 16 951 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13 400 (79.1%) had HFpEF (LVEF ≥50%). Overall, 12 812 patients (75.6%) received a BB. The median bisoprolol‐equivalent dose of BB was 5.0 (Q1–Q3: 2.5–5.0) mg with BB continuation rates of 93.1% at 2 years (in survivors). The unadjusted hazard ratio (HR) for the primary outcome did not differ between BB users and non‐users (HR 0.98, 95% confidence interval [CI] 0.91–1.05), but the adjusted HR was lower in BB users than non‐users (0.81, 95% CI 0.74–0.88), and this association was maintained across LVEF (pinteraction = 0.88). In subgroup analyses, the adjusted risk of the primary outcome was similar in BB users and non‐users with or without a history of myocardial infarction, hypertension, or a baseline heart rate <70 bpm. By contrast, a better outcome with BB use was seen in patients with atrial fibrillation compared to those without atrial fibrillation (pintreraction = 0.02).In this observational analysis of non‐randomized BB treatment, there was no suggestion that BB use was associated with worse HF outcomes in HFmrEF/HFpEF, even after extensive adjustment for other prognostic variables. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Author

Izumi, Hiroki, Matsumoto, Shingo, Liu, Jie, Tanaka, Kosuke, Mori, Shunta, Hayashi, Kumiko, Kumagai, Shogo, Shibata, Yuji, Hayashida, Takuma, Watanabe, Kana, Fukuhara, Tatsuro, Ikeda, Takaya, Yoh, Kiyotaka, Kato, Terufumi, Nishino, Kazumi, Nakamura, Atsushi, Nakachi, Ichiro, Kuyama, Shoichi, Furuya, Naoki, Sakakibara-Konishi, Jun, Okamoto, Isamu, Taima, Kageaki, Ebi, Noriyuki, Daga, Haruko, Yamasaki, Akira, Kodani, Masahiro, Udagawa, Hibiki, Kirita, Keisuke, Zenke, Yoshitaka, Nosaki, Kaname, Sugiyama, Eri, Sakai, Tetsuya, Nakai, Tokiko, Ishii, Genichiro, Niho, Seiji, Ohtsu, Atsushi, Kobayashi, Susumu S., and Goto, Koichi

Published
2021
Full Text
View/download PDF

34. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Author

Shirasawa, Masayuki, Yoshida, Tatsuya, Shimoda, Yukiko, Takayanagi, Daisuke, Shiraishi, Kouya, Kubo, Takashi, Mitani, Sachiyo, Matsumoto, Yuji, Masuda, Ken, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Ichikawa, Hitoshi, Kohno, Takashi, Yamamoto, Noboru, Matsumoto, Shingo, Goto, Koichi, Watanabe, Shun-ichi, Ohe, Yuichiro, and Motoi, Noriko

Published
2021
Full Text
View/download PDF

35. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Author

Yasuda, Hiroyuki, Ichihara, Eiki, Sakakibara-Konishi, Jun, Zenke, Yoshitaka, Takeuchi, Shinji, Morise, Masahiro, Hotta, Katsuyuki, Sato, Mineyoshi, Matsumoto, Shingo, Tanimoto, Azusa, Matsuzawa, Reiko, Kiura, Katuyuki, Takashima, Yuta, Yano, Seiji, Koyama, Junji, Fukushima, Takahiro, Hamamoto, Junko, Terai, Hideki, Ikemura, Shinnosuke, Takemura, Ryo, Goto, Koichi, and Soejima, Kenzo

Published
2021
Full Text
View/download PDF

36. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Author

Yoh, Kiyotaka, Matsumoto, Shingo, Furuya, Naoki, Nishino, Kazumi, Miyamoto, Shingo, Oizumi, Satoshi, Okamoto, Norio, Itani, Hidetoshi, Kuyama, Shoichi, Nakamura, Atsushi, Nishi, Koichi, Fukuda, Ikue, Tsuta, Koji, Hayashi, Yuichiro, Motoi, Noriko, Ishii, Genichiro, and Goto, Koichi

Published
2021
Full Text
View/download PDF

41. Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer.

Author

Kodama, Hiroaki, Murakami, Haruyasu, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Matsumoto, Shingo, Goto, Koichi, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Subjects
RNA analysis, DNA analysis, CYTOLOGY, CANCER treatment, POLYMERASE chain reaction, RETROSPECTIVE studies, DESCRIPTIVE statistics, FROZEN tissue sections, LUNG cancer, COLLECTION & preservation of biological specimens, SENSITIVITY & specificity (Statistics), SPECIALTY hospitals, SEQUENCE analysis, EPIDERMAL growth factor receptors
Abstract

Background: The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients with non‐small cell lung cancer (NSCLC). However, the suitability of cytology specimens as samples for the AmoyDx PLC panel remains unclear. We evaluated the performance of frozen cell pellets from cytology specimens (FCPs) in the Amoy 9‐in‐1 assay, a preapproval assay of the AmoyDx PLC panel. Methods: We retrospectively collected data of NSCLC patients enrolled in LC‐SCRUM‐Asia from the Shizuoka Cancer Center between September 2019 and May 2021. Results: A total of 49 cases submitted FCPs for evaluation of oncogenic driver alterations and were assessed using Amoy 9‐in‐1 and next‐generation sequencing (NGS) assays. The success rates of DNA and RNA analyses using the Amoy 9‐in‐1 were both 100%, compared with 86% and 45%, respectively, using NGS assays. Oncogenic driver alterations were detected in 27 (55%) and 23 (47%) patients using Amoy 9‐in‐1 and NGS, respectively. No inconsistent results were observed among 19 cases in which both assays showed successful detection. In the remaining 30 cases, 10 had inconsistent results: nine oncogenic driver alterations (3 MET, 2 ALK, 2 ROS1, and 2 KRAS) were detectable only in Amoy 9‐in‐1, and one epidermal growth factor receptor (EGFR) mutation was detectable only in NGS. Conclusion: FCPs can be successfully used in the AmoyDx PLC panel, with higher success rate compared with the NGS assay. The AmoyDx PLC panel may be an option in cases when insufficient tissue sample is available for the NGS assay. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Identification of Genomic Predictors of Muscle Fiber Size.

Author

Guilherme, João Paulo L. F., Semenova, Ekaterina A., Kikuchi, Naoki, Homma, Hiroki, Kozuma, Ayumu, Saito, Mika, Zempo, Hirofumi, Matsumoto, Shingo, Kobatake, Naoyuki, Nakazato, Koichi, Okamoto, Takanobu, John, George, Yusupov, Rinat A., Larin, Andrey K., Kulemin, Nikolay A., Gazizov, Ilnaz M., Generozov, Edward V., and Ahmetov, Ildus I.

Subjects
GENOME-wide association studies, SINGLE nucleotide polymorphisms, VASTUS lateralis, GENETIC variation, HUMAN genetics, SARCOPENIA, SPRINTING
Abstract

The greater muscle fiber cross-sectional area (CSA) is associated with greater skeletal muscle mass and strength, whereas muscle fiber atrophy is considered a major feature of sarcopenia. Muscle fiber size is a polygenic trait influenced by both environmental and genetic factors. However, the genetic variants underlying inter-individual differences in muscle fiber size remain largely unknown. The aim of our study was to determine whether 1535 genetic variants previously identified in a genome-wide association study of appendicular lean mass are associated with the CSA of fast-twitch muscle fibers (which better predict muscle strength) in the m. vastus lateralis of 148 physically active individuals (19 power-trained and 28 endurance-trained females, age 28.0 ± 1.1; 28 power-trained and 73 endurance-trained males, age 31.1 ± 0.8). Fifty-seven single-nucleotide polymorphisms (SNPs) were identified as having an association with muscle fiber size (p < 0.05). Of these 57 SNPs, 31 variants were also associated with handgrip strength in the UK Biobank cohort (n = 359,729). Furthermore, using East Asian and East European athletic (n = 731) and non-athletic (n = 515) cohorts, we identified 16 SNPs associated with athlete statuses (sprinter, wrestler, strength, and speed–strength athlete) and weightlifting performance. All SNPs had the same direction of association, i.e., the lean mass-increasing allele was positively associated with the CSA of muscle fibers, handgrip strength, weightlifting performance, and power athlete status. In conclusion, we identified 57 genetic variants associated with both appendicular lean mass and fast-twitch muscle fiber size of m. vastus lateralis that may, in part, contribute to a greater predisposition to power sports. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF.

Author

Matsumoto, Shingo, Yang, Mingming, Shen, Li, Henderson, Alasdair, Claggett, Brian L., Desai, Akshay S., Lefkowitz, Martin, Rouleau, Jean L., Vardeny, Orly, Zile, Michael R., Jhund, Pardeep S., Vaduganathan, Muthiah, Solomon, Scott D., and McMurray, John J.V.

Subjects
*HEART failure, *VALSARTAN, *ENTRESTO, *POLYPHARMACY, *ADVERSE health care events, *HEART failure patients
Abstract

Aims: Patients with heart failure (HF) and preserved ejection fraction (HFpEF) have a particularly high prevalence of comorbidities, often necessitating treatment with many medications. The aim of this study was to evaluate the association between polypharmacy status and outcomes in PARAGON‐HF. Methods and results: In this post hoc analysis, baseline medication status was available in 4793 of 4796 patients included in the primary analysis of PARAGON‐HF. The effects of sacubitril/valsartan, compared with valsartan, were assessed according to the number of medications at baseline: 683 non‐polypharmacy (<5 medications); 2750 polypharmacy (5–9 medications), and 1360 hyper‐polypharmacy (≥10 medications). The primary outcome was total HF hospitalizations and cardiovascular deaths. Patients with hyper‐polypharmacy were older, had more severe limitations due to HF (worse New York Heart Association class and Kansas City Cardiomyopathy Questionnaire scores), and had greater comorbidity. The non‐adjusted risk of the primary outcome was significantly higher in patients taking more medications, and similar trends were seen for HF hospitalization and cardiovascular and all‐cause death. The effect of sacubitril/valsartan versus valsartan on the primary outcome from the lowest to highest polypharmacy category was (as a rate ratio): 1.19 (0.76–1.85), 0.94 (0.77–1.15), and 0.77 (0.61–0.96) (pinteraction = 0.16). Treatment‐related adverse events were more common in patients in the higher polypharmacy categories but not more common with sacubitril/valsartan, versus valsartan, in any polypharmacy category. Conclusions: Polypharmacy is very common in patients with HFpEF, and those with polypharmacy have worse clinical status and a higher rate of non‐fatal and fatal outcomes. The benefit of sacubitril/valsartan was not diminished in patients taking a larger number of medications at baseline. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Parahydrogen-induced 13C hyperpolarizer using a flow guide for magnetic field cycling to evoke 1H-13C spin order transfer toward metabolic MRI

Author

Sawami, Koudai, primary, Naganuma, Tatsuya, additional, Yabe, Hana, additional, Taki, Toshihiko, additional, Stewart, Neil J., additional, Uchio, Yoshiki, additional, Takeda, Norihiko, additional, Hatae, Noriyuki, additional, Hashimoto, Takuya, additional, Hirata, Hiroshi, additional, and Matsumoto, Shingo, additional

Published
2024
Full Text
View/download PDF

46. O7-3 Phase II study of brigatinib in patients with TKI-naive ROS1-rearranged non-small cell lung cancer (NSCLC): Barossa study

Author

Takahashi, Toshiaki, primary, Niho, Seiji, additional, Toyozawa, Ryo, additional, Goto, Yasushi, additional, Ohashi, Kadoaki, additional, Daga, Haruko, additional, Tanaka, Hiroshi, additional, Hattori, Yoshihiro, additional, Morise, Masahiro, additional, Sakakibara-Konishi, Jun, additional, Kodani, Masahiro, additional, Ikeda, Takaya, additional, Matsumoto, Shingo, additional, Yoh, Kiyotaka, additional, Nomura, Shogo, additional, and Goto, Koichi, additional

Published
2023
Full Text
View/download PDF

47. Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry

Author

Matsumoto, Shingo, primary, McMurray, John J.V., additional, Nasu, Takahito, additional, Ishii, Shunsuke, additional, Kagiyama, Nobuyuki, additional, Kida, Keisuke, additional, Fujimoto, Wataru, additional, Kikuchi, Atsushi, additional, Ijichi, Takeshi, additional, Shibata, Tatsuhiro, additional, Ikeda, Takanori, additional, and Kanaoka, Koshiro, additional

Published
2023
Full Text
View/download PDF

49. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations

Author

Ikemura, Shinnosuke, Yasuda, Hiroyuki, Matsumoto, Shingo, Kamada, Mayumi, Hamamoto, Junko, Masuzawa, Keita, Kobayashi, Keigo, Manabe, Tadashi, Arai, Daisuke, Nakachi, Ichiro, Kawada, Ichiro, Ishioka, Kota, Nakamura, Morio, Namkoong, Ho, Naoki, Katsuhiko, Ono, Fumie, Araki, Mitsugu, Kanada, Ryo, Ma, Biao, Hayashi, Yuichiro, Mimaki, Sachiyo, Yoh, Kiyotaka, Kobayashi, Susumu S., Kohno, Takashi, Okuno, Yasushi, Goto, Koichi, Tsuchihara, Katsuya, and Soejima, Kenzo

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results